Clinical management of asthma and chronic obstructive pulmonary disease (COPD) has primarily relied on the use of beta 2 adrenergic receptor agonists (bronchodilators) and corticosteroids, and more recently, monoclonal antibody therapies (biologics) targeting specific cytokines and their functions. Although these approaches provide relief from exacerbations, questions remain on their long-term efficacy and safety. Furthermore, current therapeutics do not address progressive airway remodeling (AR), a key pathological feature of severe obstructive lung disease. Strikingly, agonists of the bitter taste receptors (TAS2Rs) deliver robust bronchodilation, curtail allergen-induced inflammatory responses in the airways and regulate airway smooth muscle (ASM) cell proliferation and mitigate features of AR
Recommended CitationNayak, Ajay P.; Shah, Sushrut D.; Michael, James V.; and Deshpande, Deepak A., "Bitter Taste Receptors for Asthma Therapeutics." (2019). Center for Translational Medicine Faculty Papers. Paper 61.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.